Allogene Therapeutics’ CAR-T therapy removed all remaining detectable lymphoma cells in just over half of treated patients, according to an early look at the Phase

Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as well as diagnostic agents

BioNTech rolled out positive Phase 2 data Monday morning for an antibody-drug conjugate the company hopes can elbow aside Enhertu in certain populations. BioNTech said

Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.